within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DI01_CeftobiproleMedocaril;

model CeftobiproleMedocaril
  extends Pharmacolibrary.Drugs.ATC.J.J01DI01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01DI01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ceftobiprole medocaril is a cephalosporin antibiotic prodrug that is rapidly converted in vivo to its active form, ceftobiprole. It is used for the treatment of hospital-acquired and community-acquired pneumonia and has activity against a wide spectrum of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved in several countries in Europe and elsewhere, but not currently approved for use in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects, with values based on a population pharmacokinetic analysis after intravenous infusion.</p><h4>References</h4><ol><li><p>Azanza Perea, JR, &amp; Sádaba Díaz de Rada, B (2019). Ceftobiprole: pharmacokinetics and PK/PD profile. <i>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</i> 32 Suppl 3(Suppl 3) 11–16. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31364336/\">https://pubmed.ncbi.nlm.nih.gov/31364336</a></p></li><li><p>Scheeren, TW (2015). Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia. <i>Future microbiology</i> 10(12) 1913–1928. DOI:<a href=\"https://doi.org/10.2217/fmb.15.115\">10.2217/fmb.15.115</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26573022/\">https://pubmed.ncbi.nlm.nih.gov/26573022</a></p></li><li><p>Torres, A, et al., &amp; Pea, F (2016). Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations. <i>Clinical pharmacokinetics</i> 55(12) 1507–1520. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0418-z\">10.1007/s40262-016-0418-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27272266/\">https://pubmed.ncbi.nlm.nih.gov/27272266</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end CeftobiproleMedocaril;
